Dikel Nevin Hande, Yumusak Erhan, Gokcinar Nesrin Buyuktortop
Department of Ophthalmology, Karaman State Hospital, Karaman, Turkey.
Department of Ophthalmology, University of Health Sciences, Gulhane Faculty of Medicine, Ankara, Turkey.
Beyoglu Eye J. 2019 Dec 27;4(3):141-148. doi: 10.14744/bej.2019.40412. eCollection 2019.
The present study aims to compare the long-term efficacy and safety results of intravitreal ranibizumab (RAN), dexamethasone intravitreal implant (DEX) and intravitreal triamcinolone acetonide (IVTA) injections in macular edema due to branch retinal vein occlusion (BRVO).
In this retrospective study, one eye each of 43 patients who were treated with intravitreal injections for macular edema secondary to BRVO was recruited into one of the study groups: RAN group (n=17), DEX group (n=16) and IVTA group (n=10). All patients were followed-up for 12 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT) and intraocular pressure (IOP) at month 1, 3, 6, and 12 were compared with baseline.
The BCVA increased significantly in the RAN and DEX groups at all visits (all p<0.05). BCVA increase in the IVTA group was significant only at month 1 and 6. CMT decreased significantly in all groups at the end of one year of follow-up (p=0.007; p=0.001; p=0.044, respectively). SFCT significantly decreased in all groups at month 1 (all p<0.05). IOP significantly increased in none, 18.8%, 30% of the patients in the RAN, DEX and IVTA groups, respectively. Cataract surgery was performed in none of the patients, 6.3%, and 30% of the patients in the RAN, DEX, and IVTA groups, respectively.
BCVA increase was more prominent in both of the RAN and DEX groups than in the IVTA group. DEX may decrease the injection burden; however, ranibizumab may be a safer choice.
本研究旨在比较玻璃体内注射雷珠单抗（RAN）、地塞米松玻璃体内植入物（DEX）和曲安奈德玻璃体内注射（IVTA）治疗视网膜分支静脉阻塞（BRVO）所致黄斑水肿的长期疗效和安全性结果。
在这项回顾性研究中，43例因BRVO继发黄斑水肿接受玻璃体内注射治疗的患者，每例患者的一只眼睛被纳入以下研究组之一：RAN组（n = 17）、DEX组（n = 16）和IVTA组（n = 10）。所有患者均随访12个月。将第1、3、6和12个月时的最佳矫正视力（BCVA）、中心黄斑厚度（CMT）、黄斑中心凹下脉络膜厚度（SFCT）和眼压（IOP）与基线进行比较。
RAN组和DEX组在所有随访时BCVA均显著提高（所有p<0.05）。IVTA组仅在第1个月和第6个月时BCVA提高显著。随访一年结束时，所有组的CMT均显著降低（分别为p = 0.007；p = 0.001；p = 0.044）。所有组在第1个月时SFCT均显著降低（所有p<0.05）。RAN组、DEX组和IVTA组分别有0%、18.8%和30%的患者眼压显著升高。RAN组、DEX组和IVTA组分别有0%、6.3%和30%的患者接受了白内障手术。
RAN组和DEX组的BCVA提高均比IVTA组更显著。DEX可能会减轻注射负担；然而，雷珠单抗可能是更安全的选择。
